Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

Blood

Volumn 127, Issue 6, 2016, Pages 703-712

  Deininger, Michael W ^a   Hodgson, J Graeme ^b   Shah, Neil P ^c   Cortes, Jorge E ^d   Kim, Dong Wook ^e   Nicolini, Franck E ^f   Talpaz, Moshe ^g   Baccarani, Michele ^h   Müller, Martin C ⁱ   Li, Jin ^j   Parker, Wendy T ^o   Lustgarten, Stephanie ^b   Clackson, Tim ^b   Haluska, Frank G ^b   Guilhot, Francois ^k   Kantarjian, Hagop M ^d   Soverini, Simona ^l   Hochhaus, Andreas ^m   Hughes, Timothy P ^n,o   Rivera, Victor M ^b   Branford, Susan ^o,p   more..

^a UNIVERSITY OF UTAH   (United States)

^b ARIAD PHARMACEUTICALS INC   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^e The Catholic University of Korea   (South Korea)

^f CENTRE HOSPITALIER LYON SUD   (France)

^g UNIVERSITY OF MICHIGAN   (United States)

^h UNIVERSITY OF BOLOGNA   (Italy)

ⁱ UNIVERSITY OF HEIDELBERG   (Germany)

^j MolecularMD   (United States)

^k POITIERS UNIVERSITY HOSPITAL   (France)

^l UNIVERSITY OF BOLOGNA   (Italy)

^m JENA UNIVERSITY HOSPITAL   (Germany)

ⁿ SOUTH AUSTRALIAN HEALTH AND MEDICAL RESEARCH INSTITUTE   (Australia)

^o UNIVERSITY OF ADELAIDE   (Australia)

^p UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL 1 PROTEIN; BCR ABL PROTEIN; DASATINIB; IMATINIB; NILOTINIB; PONATINIB; UNCLASSIFIED DRUG; IMIDAZOLE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIDAZINE DERIVATIVE;

ARTICLE; CHRONIC MYELOID LEUKEMIA; CHRONIC PHASE CHRONIC MYELOID LEUKEMIA; CYTOGENETICS; DRUG EFFICACY; DRUG RESPONSE; FOLLOW UP; GENE FREQUENCY; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MISSENSE MUTATION; NEXT GENERATION SEQUENCING; PREVALENCE; PRIORITY JOURNAL; ADJUVANT CHEMOTHERAPY; AMINO ACID SUBSTITUTION; CLINICAL TRIAL; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE; GENETICS; HIGH THROUGHPUT SEQUENCING; LEUKEMIA, MYELOID, CHRONIC-PHASE; MULTICENTER STUDY; MUTATION; NEOADJUVANT THERAPY; PHASE 2 CLINICAL TRIAL; PHYSIOLOGY; PROCEDURES;

AMINO ACID SUBSTITUTION; CHEMOTHERAPY, ADJUVANT; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FUSION PROTEINS, BCR-ABL; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; IMIDAZOLES; LEUKEMIA, MYELOID, CHRONIC-PHASE; MUTATION; NEOADJUVANT THERAPY; PROTEIN KINASE INHIBITORS; PYRIDAZINES;

EID: 84959331313     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-08-660977     Document Type: Article

References (29)

1. Druker BJ. Circumventing resistance to kinaseinhibitor therapy. N Engl J Med. 2006;354(24): 2594-2596.
2. O'Hare T, Zabriskie MS, Eiring AM, Deininger MW. Pushing the limits of targeted therapy in chronic myeloid leukaemia. Nat Rev Cancer. 2012;12(8):513-526.
3. Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872-884.
4. Soverini S, Hochhaus A, Nicolini FE, et al. BCRABL kinase domain mutation analysis in chronic myeloid leukemia patients treated with tyrosine kinase inhibitors: recommendations from an expert panel on behalf of European LeukemiaNet. Blood. 2011;118(5):1208-1215.
5. Zabriskie MS, Eide CA, Tantravahi SK, et al. BCR-ABL1 compound mutations combining key kinase domain positions confer clinical resistance to ponatinib in Ph chromosome-positive leukemia. Cancer Cell. 2014;26(3):428-442.
6. Shah NP, Skaggs BJ, Branford S, et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. J Clin Invest. 2007;117(9):2562-2569.
7. Bradeen HA, Eide CA, O'Hare T, et al. Comparison of imatinib mesylate, dasatinib (BMS- 354825), and nilotinib (AMN107) in an N-ethyl-Nnitrosourea (ENU)-based mutagenesis screen: high efficacy of drug combinations. Blood. 2006; 108(7):2332-2338.
8. O'Hare T, Shakespeare WC, Zhu X, et al. AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance. Cancer Cell. 2009;16(5):401-412.
9. Muller MC, Cortes JE, Kim DW, et al. Dasatinib treatment of chronic-phase chronic myeloid leukemia: Analysis of responses according to preexisting BCR-ABL mutations. Blood. 2009; 114(24):4944-4953.
10. Hughes T, Saglio G, Branford S, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase. J Clin Oncol. 2009;27(25): 4204-4210.
11. Parker WT, Lawrence RM, Ho M, et al. Sensitive detection of BCR-ABL1 mutations in patients with chronic myeloid leukemia after imatinib resistance is predictive of outcome during subsequent therapy. J Clin Oncol. 2011;29(32):4250-4259.
12. Soverini S, De Benedittis C, Machova Polakova K, et al. Unraveling the complexity of tyrosine kinase inhibitor-resistant populations by ultradeep sequencing of the BCR-ABL kinase domain. Blood. 2013;122(9):1634-1648.
13. Parker WT, Ho M, Scott HS, Hughes TP, Branford S. Poor response to second-line kinase inhibitors in chronic myeloid leukemia patients with multiple low-level mutations, irrespective of their resistance profile. Blood. 2012;119(10): 2234-2238.
14. Parker WT, Phillis SR, Yeung DT, Hughes TP, Scott HS, Branford S. Many BCR-ABL1 compound mutations reported in chronic myeloid leukemia patients may actually be artifacts due to PCR-mediated recombination. Blood. 2014; 124(1):153-155.
15. Cortes JE, Kantarjian H, Shah NP, et al. Ponatinib in refractory Philadelphia chromosome-positive leukemias. N Engl J Med. 2012;367(22): 2075-2088.
16. Cortes JE, Kim DW, Pinilla-Ibarz J, et al; PACE Investigators. A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias. N Engl J Med. 2013;369(19):1783-1796.
17. O'Hare T, Zabriskie MS, Eide CA, et al. The BCRABL35INS insertion/truncation mutant is kinaseinactive and does not contribute to tyrosine kinase inhibitor resistance in chronic myeloid leukemia. Blood. 2011;118(19):5250-5254.
18. Sherbenou DW, Hantschel O, Kaupe I, et al. BCR-ABL SH3-SH2 domain mutations in chronic myeloid leukemia patients on imatinib. Blood. 2010;116(17):3278-3285.
19. Gaillard JB, Arnould C, Bravo S, et al. Exon 7 deletion in the bcr-abl gene is frequent in chronic myeloid leukemia patients and is not correlated with resistance against imatinib. Mol Cancer Ther. 2010;9(11):3083-3089.
20. Kastner R, Zopf A, Preuner S, et al. Rapid identification of compound mutations in patients with Philadelphia-positive leukaemias by longrange next generation sequencing. Eur J Cancer. 2014;50(4):793-800.
21. Parker WT, Yeoman AL, Jamison BA, et al. BCRABL1 kinase domain mutations may persist at very low levels for many years and lead to subsequent TKI resistance. Br J Cancer. 2013; 109(6):1593-1598.
22. Hanfstein B, Muller MC, Kreil S, et al. Dynamics of mutant BCR-ABL-positive clones after cessation of tyrosine kinase inhibitor therapy. Haematologica. 2011;96(3):360-366.
23. Gruber FX, Lamark T, Anonli A, et al. Selecting and deselecting imatinib-resistant clones: observations made by longitudinal, quantitative monitoring of mutated BCR-ABL. Leukemia. 2005;19(12):2159-2165.
24. Branford S, Yeung DT, Parker WT, et al. Prognosis for patients with CML and .10% BCRABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline. Blood. 2014;124(4): 511-518.
25. Hehlmann R, Muller MC, Lauseker M, et al. Deep molecular response is reached by the majority of patients treated with imatinib, predicts survival, and is achieved more quickly by optimized high-dose imatinib: results from the randomized CML-study IV. J Clin Oncol. 2014; 32(5):415-423.
26. Hanfstein B, Shlyakhto V, Lauseker M, et al; SAKK and the German CML Study Group. Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib. Leukemia. 2014; 28(10):1988-1992.
27. Hochhaus A, Pinilla-Ibarz J, Kim D-W, et al. Clinical impact of dose modification and dose intensity on response to ponatinib in patients with Philadelphia chromosome?positive leukemias [abstract]. J Clin Oncol. 2014;32(15 suppl). Abstract 7084.
28. Cortes JE, Kim D, Pinilla-Ibarz J, et al. Long-term follow-up of ponatinib efficacy and safety in the phase 2 PACE Trial [abstract]. Blood. 2014; 124(21 suppl). Abstract 3135.
29. Gozgit MJ, Schrock BA, Chen T, Clackson T, Rivera MV. Comprehensive analysis of the in vitro potency of ponatinib, and all other approved BCRABL tyrosine kinase inhibitors (TKIs), against a panel of single and compound BCR-ABL mutants [abstract]. Blood. 2013;122(21 suppl). Abstract 3992.